# A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

> **NCT05322577** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 72 (actual)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Cancer

## Interventions

- **DRUG:** Bemarituzumab
- **DRUG:** CAPOX
- **DRUG:** SOX
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05322577
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-17
- **Primary completion:** 2025-11-21
- **Final completion:** 2026-08-12
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05322577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05322577, "A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05322577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*